ClinicalTrials.gg
RecruitingNCT06792552Updated Aug 17, 2026

A Phase I Study of SIM0505 in Participants With Advanced Solid Tumors

A Phase 1 interventional study of SIM0505 for injection and SIM0505 for injection in Advanced Solid Tumors, Platinum Resistant Ovarian Cancer and Fallopian Tube Cancer, sponsored by NextCure, Inc.. Recruiting at 17 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-17.

Sponsored by NextCure, Inc. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Feb 2025; still recruiting 1 year 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
738
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 589 studies in Fallopian Tube Neoplasms with a site in United States — 63 open to participants now, 130 under way, 24 of them phase 3. Fallopian Tube Neoplasms · United States.

Planned enrollment
22nd of 513
738 · median 40
Started
2025
with 18 others
Phase 1
181 of 589
14 open now
Primary completion
2028-02
later than 94 of 129 live
Registered
568th of 589
by date

Among the 589 studies in Fallopian Tube Neoplasms with a site in United States, this one is the 22nd largest by planned enrollment of the 513 interventional ones that give a count, is one of 19 that started in 2025, is one of 181 in phase 1, reaches primary completion later than 94 of the 129 other live ones, and was the 568th registered.

Fallopian Tube Neoplasms

835 studies on the registry are indexed under Fallopian Tube Neoplasms; 131 are open to participants now.

Browse Fallopian Tube Neoplasms studies →

Open to participants now

63 of the 589 studies in Fallopian Tube Neoplasms with a site in United States are open now. Recruiting first, the newest first:

57 more — sign in →

All 63 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 106 Fallopian Tube Neoplasms studies recruiting now, 88 (83%) set no upper age limit and 10 (9%) stop at 75 or younger; 6 take children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 589 studies in Fallopian Tube Neoplasms with a site in United States, or all of them as a file.
02

Study summary

This is an open-label, multicenter phase 1 study to evaluate the safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of SIM0505 in Adult Participants with Advanced Solid Tumors

03

Conditions studied

  • Advanced Solid Tumors
  • Platinum Resistant Ovarian Cancer
  • Fallopian Tube Cancer
  • Renal Cell Carcinoma (RCC)
  • Papillary Renal Cell Carcinoma (Prcc)
  • Uterine Serous Carcinoma (USC)
  • NSCLC (Non-small Cell Lung Cancer)
  • Primary Peritoneal Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Written is obtained prior to any procedures that are not considered standard of care.
  2. ≥18 years of age.
  3. In Part 1:

    1. Participants with or cytologically confirmed advanced solid tumors, who have failed or are ineligible for standard of care therapies.
    2. Have progressed on at least one prior systematic anti-tumor regimen, and presence of at least one evaluable lesion according to Version 1.1. are required in the backfill period.
    3. In the backfill period, eligible tumor types are limited to high-grade serous ovarian cancer, high-grade endometrioid ovarian cancer, USC, clear cell RCC, papillary RCC and adenocarcinoma of NSCLC without actionable mutation of epidermal growth factor receptor (EGFR). For participants with NSCLC, presence of CDH6 expression through immunohistochemical examination of tumor tissue by central laboratory is required.
  4. In Part 2: Participants must have a diagnosis of specific type of or locally advanced solid tumors and have progressed on or cannot benefit from the most recent systematic anti-tumor regimen (unless otherwise specified), with presence of at least one measurable lesion according to RECIST Version 1.1.

    Platinum-resistant ovarian cancer cohort:

    1. Participants with histologically or cytologically confirmed high-grade serous ovarian cancer, high-grade endometrioid ovarian cancer, primary peritoneal cancer, or fallopian tube cancer.
    2. Have platinum-resistant disease, defined as: participants who have only had 1 line of platinum-based therapy must have received at least 4 cycles of platinum, must have had a best response of CR or PR, and then progressed between >90 days and ≤180 days after the date of the last dose of platinum; participants who have received ≥2 lines of platinum therapy must have progressed ≤180 days after the date of the last dose of platinum.
    3. At least one containing anti-VEGF therapy (e.g., bevacizumab or suvemcitug or their biosimilar), unless the participant is not eligible for treatment with anti- angiogenic treatment due to precautions/intolerance. Has had prior poly-ADP ribose polymerase (PARP) inhibitors for subjects with documented breast cancer gene (BRCA) mutation (germline and/or somatic), unless the subject is not eligible for treatment with a PARP inhibitor. Has had prior treatment with mirvetuximab soravtansine for participants with documented high folate receptor alpha expression, unless the subject is not eligible for treatment with mirvetuximab soravtansine due to precautions/intolerance, or if the treatment is not approved or available locally. In the PROC cohort, topoisomerase inhibitor payload ADC-pretreated participants should have received at least one prior topoisomerase inhibitor payload ADC.

    Renal cell carcinoma cohort:

    1. Participants with histologically- or cytologically-confirmed clear cell RCC or papillary RCC.
    2. For clear cell RCC: Participants who have progressed on or after systemic treatment including a programmed cell death protein 1 or programmed death ligand 1 (/PD-L1) checkpoint inhibitor and a vascular endothelial growth factor-tyrosine kinase inhibitor (VEGF-TKI), either given concurrently or in separate lines of therapy.
    3. For papillary RCC: Participants without any prior systemic treatment is acceptable.

    Uterine serous carcinoma cohort:

    1. Participants with histologically- or cytologically-confirmed USC.
    2. Have progressed on or after systemic treatment that contained platinum-based chemotherapy.

    Non-Small Cell Lung Cancer cohort:

    1. Participants with histologically- or cytologically-confirmed adenocarcinoma of NSCLC without actionable mutation of EGFR.
    2. Presence of CDH6 expression through immunohistochemical examination of tumor tissue.
    3. For participants without actionable mutations: Have progressed on or after systemic treatment including anti-PD-1/PD-L1 antibody and platinum-based chemotherapy, either given concurrently or in separate lines of therapy. Progression within 6 months after completion of therapy is considered failure of first-line therapy.
    4. For participants with actionable mutations other than EGFR: Have failed at least one established standard anti-cancer targeted therapy, anti-PD-1/PD-L1 antibody and platinum-based chemotherapy (PD-1/PD-L1 and chemotherapy either given concurrently or in separate lines of therapy) or in the opinion of the Investigator have been considered ineligible for a particular form of standard of care therapy on medical grounds.
  5. (ECOG) performance status score of 0 or 1.
  6. of ≥12 weeks.
  7. Have adequate organ function as indicated by the laboratory values listed within the protocol.
  8. Women of (WOCBP) must have a negative serum pregnancy test within 72 hours prior to the start of study treatment. WOCBP or male participants who have sexual relations with WOCBP are required to use highly effective methods, and agree to refrain from donating sperm/egg from signing of informed consent through 180 days after the last dose of study treatment.
  9. Able to provide tumor tissue sample (archival or newly obtained core or excisional ). For Part 1: At biomarker-screening (for NSCLC) or screening (for non-NSCLC) visit of a tumor lesion not previously irradiated for CDH6 testing.

For Part 2: Willing to undergo fresh tumor biopsy at biomarker-screening visit (for NSCLC) and screening visit (non-NSCLC) from a lesion that can be biopsied at an acceptable clinical risk as judged by the investigator.

Exclusion criteria

Exclusion Criteria:

  1. For Part 2: has clear cell, mucinous or sarcomatous histology, mixed tumors containing any histology, or low-grade/borderline ovarian cancer; mixed nonsmall cell and small cell carcinoma, or adenosquamous cell lung cancer with an adenocarcinoma component \<50% (the participant is eligible if the adenocarcinoma component is ≥50%).
  2. For Part 2: Participants with primary platinum ovarian cancer, defined as disease that did not respond to (CR or PR) or has progressed within 3 months of the last dose of platinum-containing chemotherapy.
  3. Any other within 2 years prior to the first dose of the study treatment except for localized cancers that are considered to have been cured and in the opinion of the Investigator present a low risk for recurrence.
  4. Known untreated and/or . Participants are eligible if CNS metastases have been treated and participants have neurologically returned to baseline (except for residual signs or symptoms related to the CNS treatment). In addition, participants must have been either off , or on a stable or decreasing dose of ≤10 mg daily prednisone (or equivalent) for at least 2 weeks prior to the first dose of study treatment. Imaging performed within 28 days prior to the first dose of study treatment must document radiographic stability of CNS lesions and be performed after completion of any CNS-directed therapy.
  5. History of bowel obstruction within 3 months prior to the first dose of study treatment.
  6. Known psychiatric disorder or drug abuse that would interfere the study requirements.
  7. Uncontrollable pleural effusion, pericardial effusion, or ascites requiring drainage or medical intervention within 4 weeks before the first dose of study treatment.
  8. Any active infection requires systemic treatment via intravenous infusion within 2 weeks prior to the first dose of study treatment.
  9. History of non-infectious pneumonitis that has required a course of oral or intravenous steroids to assist with recovery, or interstitial lung disease (ILD) or severe obstructive pulmonary disease.
  10. Prior exposure to other CDH6-targeted agents.
  11. Prior exposure to an ADC with a topoisomerase I inhibitor payload (e.g., raludotatug deruxtecan/DS-6000) for all cohorts except for the topoisomerase inhibitor payload ADC-pretreated participants in PROC cohort.
  12. Has not recovered (i.e., to version 5.0 Grade 1 or to baseline) from previous anticancer therapy-induced AEs. Grade ≤2 AEs with no impact on participant safety are exceptions to this criterion and may qualify for the study.
  13. Currently participating or has participated in a study of an agent or using an investigational device within 4 weeks of first dose of SIM0505.
  14. Major surgery within 2 weeks of receiving the first dose of study treatment.
  15. Has received prior anti-cancer therapies within the following time frames prior to the first dose of study treatment: previous cytotoxic therapy, anticancer targeted small molecules (e.g., tyrosine kinase inhibitors), hormonal agents within 2 weeks; anti-cancer antibody or ADC within 5 half-lives or 4 weeks (whichever is shorter) prior to the first dose of study treatment; Chinese medicines/herbal preparations with anticancer indication taken within 2 weeks; and/or radiation therapy within 2 weeks for focal radiation or within 4 weeks for wide-field radiation.
  16. Use of any therapy within 4 weeks prior to the first dose of study treatment.
  17. Administration of strong or moderate inhibitors or drugs with known risk of Torsades de Pointes (TdP) ≤ 7 days or 3 half-lives (whichever is longer) prior to the first dose of SIM0505.
  18. Known (HIV) infection or known acquired immunodeficiency syndrome (AIDS).
  19. Active or infection.
  20. Participants with cardiovascular diseases.
  21. History of allogeneic organ transplantation or .
  22. Known to study drug or any of the .
  23. Participant is pregnant or breastfeeding.
  24. Other conditions that researchers consider inappropriate for inclusion.
Terms in these criteria, in plain language(29)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
738 participants (estimated)

Study arms

  • Experimental
    SIM0505 mono dose escalation

    Every 21 days is one cycle. Multiple dose levels of SIM0505 will be explored in dose escalation, and determine the maximum tolerated dose.

    Drug: SIM0505 for injection

  • Experimental
    SIM0505 mono dose optimization - PROC

    Every 21 days is one cycle. 2-3 dose levels of SIM0505 will be explored in dose optimization, and determine the recommended dose (RD) of SIM0505 and evaluate the preliminary anti-tumor activity of SIM0505 in PROC.

    Drug: SIM0505 for injection

  • Experimental
    SIM0505 mono dose optimization - RCC

    Every 21 days is one cycle. 2 dose levels of SIM0505 will be explored in dose optimization, and determine the recommended dose (RD) of SIM0505 and evaluate the preliminary anti-tumor activity of SIM0505 in RCC.

    Drug: SIM0505 for injection

  • Experimental
    SIM0505 mono dose optimization - USC

    Every 21 days is one cycle. 2 dose levels of SIM0505 will be explored in dose optimization, and determine the recommended dose (RD) of SIM0505 and evaluate the preliminary anti-tumor activity of SIM0505 in USC.

    Drug: SIM0505 for injection

  • Experimental
    SIM0505 mono dose optimization - NSCLC

    Every 21 days is one cycle. 2 dose levels of SIM0505 will be explored in dose optimization, and determine the recommended dose (RD) of SIM0505 and evaluate the preliminary anti-tumor activity of SIM0505 in NSCLC.

    Drug: SIM0505 for injection

Interventions

  • DrugSIM0505 for injection

    Every 21 days is one cycle. Multiple dose levels of SIM0505 will be explored in dose escalation, and determine the maximum tolerated dose.

  • DrugSIM0505 for injection

    Every 21 days is one cycle. 2-3 dose levels of SIM0505 will be explored in dose optimization, and determine the recommended dose (RD) of SIM0505 and evaluate the preliminary anti-tumor activity of SIM0505

06

What researchers measure

Primary outcomes

  1. dose escalation: Dose-limiting toxicity (DLT)

    Time frame: At the end of Cycle 1 (each cycle is 21 days)

  2. dose escalation & optimization: Adverse events (AEs)

    Time frame: the whole dose escalation phase,an average of 2 year

  3. dose optimization:Objective response rate (ORR)

    Time frame: the whole dose optimization phase,an average of 1.5 year

07

Study locations

6 of 17 sites recruiting
  • Sarah Cannon Research Institute (SCRI) - Lake Nona
    Orlando, Florida 32827, United States
    Active, not recruiting

    Not enrolling at this site.

  • Emory Winship Cancer Institute
    Atlanta, Georgia 30322, United States
    Active, not recruiting

    Not enrolling at this site.

  • University Medical Center of New Orleans LSU-LCMC Health Cancer Center
    New Orleans, Louisiana 70112, United States
    Active, not recruiting

    Not enrolling at this site.

  • Dana-Farber Cancer Institute
    Boston, Massachusetts 02215, United States
    Active, not recruiting

    Not enrolling at this site.

  • Hackensack University Medical Center
    Hackensack, New Jersey 07601, United States
    Active, not recruiting

    Not enrolling at this site.

  • Roswell Park Cancer Institute
    Buffalo, New York 14263, United States
    Active, not recruiting

    Not enrolling at this site.

  • Icahn School of Medicine at Mount Sinai
    New York, New York 10128, United States
    Active, not recruiting

    Not enrolling at this site.

  • Sarah Cannon Research Institute (SCRI) - Nashville
    Nashville, Tennessee 37203, United States
    Active, not recruiting

    Not enrolling at this site.

  • UT Health San Antonio - Mays Cancer Center
    San Antonio, Texas 78229, United States
    Active, not recruiting

    Not enrolling at this site.

  • The first medical center of PLA general hospital
    Beijing, Beijing Municipality 100000, China
    Recruiting
    • Yi Hu, Ph D · Contact
  • Liaoning Cancer Hospital & Institute
    Shenyang, China 110092, China
    Not yet recruiting
    • Hongxu Liu · Contact
  • The Fourth Hospital of Hebei Medical University (Heibei Tumor Hospital)
    Shijiazhuang, China 050010, China
    Not yet recruiting
    • Ziqiang Tian · Contact
    • Mingxia Wang · Contact
  • Sun Yat-sen University Cancer Center
    Guangzhou, Guangdong 510060, China
    Recruiting
    • Jundong Li · Contact
  • HunanCancer Hospital
    Changsha, Hunan 430100, China
    Recruiting
    • Dihong Tang · Contact
    • Shusuan Jiang · Principal investigator
  • Cancer Hospital of Shandong First Medical University
    Jinan, Shandong 250117, China
    Recruiting
    • Yan Zhang · Contact
  • Affiliated Hospital of Jining Medical University
    Jining, Shandong 272000, China
    Recruiting
    • Xiaowei Liu · Contact
  • Fudan University Shanghai Cancer Center
    Shanghai, Shanghai Municipality 200032, China
    Recruiting
    • Xiaohua Wu, Ph D · Contact
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2025 (actual). Primary completion is estimated for Feb 2028, 36 months after the start.

Of 31 industry-sponsored phase 1 interventional studies under Fallopian Tube Neoplasms, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 57. This study's planned 36 months is below that.

Counting every sponsor, half of 96 studies reached it within 54 months; a quarter within 36 and three quarters within 83.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 13, 2025
First posted
Jan 24, 2025
StartActual
Feb 26, 2025
Primary completionEst.
Feb 2028
CompletionEst.
Aug 2028
Last update
Aug 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06792552
Lead sponsor
NextCure, Inc.
Collaborators
Shanghai Simcere Zaiming Biotechnology Co., Ltd.
Responsible party
Sponsor
First posted
Jan 24, 2025
Start date
Feb 26, 2025
Primary completion
Feb 2028 (estimated)
Completion
Aug 2028 (estimated)
Last update
Aug 17, 2026

Study contacts

Udayan Guha, PhD, MD
Contact
NCClin@nextcure.com
301-919-4218
Siyuan Qian
Contact
Siyuan.Qian@zaiming.com

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion